Newer Strategies for the Treatment of Heparin‐Induced Thrombocytopenia

Publisher Website
Google Scholar
Abstract
Treatment with heparin is associated with two types of thrombocytopenia. One is a mild, transient, nonimmune disorder, generally without adverse clinical consequence. The other, known as heparin‐induced thrombocytopenia (HIT), is a potentially serious, immunoglobulin‐mediated reaction with a paradoxic high risk of thromboembolic events. Various treatment options for HIT are discussed, with emphasis on pharmacologic approaches that control the increased thrombin generation characteristic of this disorder.